1.INTRODUCTION
Complex regional pain syndrome (CRPS) is a common and disabling
persistent pain condition results from an abnormal tissue response to
injury, and increased sensitization of the central and peripheral
nervous systems with various symptoms including swelling, limited joint
range of motion, autonomic dysregulation and trophic changes in the
affected limb. Several cases of CRPS have been reported after
vaccination [1,2].
After the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)
pandemic, several new and effective vaccines were approved in a
relatively short period. However, the safety profile has been subject of
concern.
This report describes a young man patient who developed complex regional
pain syndrome (CRPS) of the right knee after receiving the second dose
of messenger RNA— BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine.